Status:
COMPLETED
Prescription Medication Interactions
Lead Sponsor:
Sharon Walsh
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid Use
Sedative Use
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This study will examine the effects of doses of opioid/placebo and doses of sedative/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings...
Detailed Description
Gabapentin and oxycodone are commonly used in combination for the treatment of chronic pain. Gabapentin is now widely misused/abused with studies indicating that gabapentin abuse is especially common ...
Eligibility Criteria
Inclusion
- Healthy adults, ages 18-55
- Current non-medical use of opioids and sedatives
Exclusion
- Physical dependence on opioids, alcohol, or benzodiazepines/sedatives/hypnotics
- Seeking treatment for drug use
- Significant medical problems
Key Trial Info
Start Date :
March 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 6 2023
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT04315181
Start Date
March 25 2019
End Date
May 6 2023
Last Update
October 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center on Drug and Alcohol Research
Lexington, Kentucky, United States, 40508